コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 Motor examination of the Unified Parkinson's Disease Rating Scale.
2 gait impairment that were based on the motor Unified Parkinson's Disease Rating Scale.
3 nts of motor effect were performed using the Unified Parkinson's Disease Rating Scale.
4 hysical and neurological examination and the Unified Parkinson's Disease Rating Scale.
5 assessed proximate to death using a modified Unified Parkinson's Disease Rating Scale.
6 xtrapyramidal signs was determined using the Unified Parkinson's Disease Rating Scale.
7 hanges in clinical status as measured by the Unified Parkinson's Disease Rating Scale.
8 disease severity, as measured by the sum of Unified Parkinson's Disease Rating Scale Activities of D
9 up of 50 controls who were examined with the Unified Parkinson's Disease Rating Scale an average of 2
10 t disorder score (Movement Disorders Society Unified Parkinson's Disease Rating Scale) and attention,
11 and the change in PD clinical scale scores (Unified Parkinson's Disease Rating Scale) and DAT imagin
12 e (including "on time with dyskinesia"), the Unified Parkinson's Disease Rating Scale, and a Clinical
13 d timed up-and-go tests, motor scores on the Unified Parkinson's Disease Rating Scale, and number of
14 assessed using the Hoehn and Yahr scale, the unified Parkinson's disease rating scale, and the Epwort
15 or Experiences of Daily Living, the original Unified Parkinson's Disease Rating Scale, and the Parkin
16 it Disorder score-Movement Disorders Society Unified Parkinson's Disease Rating Scale), attention and
17 ated with PD severity approximated using the Unified Parkinson's Disease Rating Scale but also with t
18 Mental Status, modified motor subtest of the Unified Parkinson's Disease Rating Scale, detailed neuro
19 ) years; 21 were male, three female and mean Unified Parkinson's Disease Rating Scale III score (moto
20 ters were equally effective in improving the Unified Parkinson's disease Rating Scale III scores rela
22 onth evaluation in the motor subscore of the Unified Parkinson's Disease Rating Scale in the practica
23 ne to 12 months in the motor subscore of the unified Parkinson's disease rating scale in the practica
24 e and final visits in motor component of the Unified Parkinson's Disease Rating Scale in the practica
25 t Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale item-adjusted m
26 difference in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) mot
27 ed scores from the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) par
28 ons, including the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) par
29 re rated using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Par
30 assessment of the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS), to
31 th motor symptoms (Movement Disorder Society Unified Parkinson's Disease Rating Scale, MDS-UPDRS III)
32 = .046), and higher mean (SD) scores on the Unified Parkinson's Disease Rating Scale motor part III
35 ange, 38.5-95.9 years), and the median total Unified Parkinson's Disease Rating Scale motor score was
36 with relatively more severe disease (higher Unified Parkinson's Disease Rating Scale motor score).
37 ility were all associated with a more severe Unified Parkinson's Disease Rating Scale motor score.
39 correlated significantly and comparably with Unified Parkinson's Disease Rating Scale motor scores.
40 ression Scale, and Movement Disorder Society Unified Parkinson's Disease Rating Scale motor scores; 0
41 ion, and parkinsonian motor signs (using the Unified Parkinson's Disease Rating Scale motor subscale
42 uring stimulation (-2.5 motor portion of the Unified Parkinson's Disease Rating Scale (mUPDRS) points
43 t Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale Nonmotor Experi
44 ceiving medication (P=0.01 for scores on the Unified Parkinson's Disease Rating Scale; P=0.006 for th
45 Patients were assessed serially with the Unified Parkinson's Disease Rating Scale Part I depressi
46 ior disorder (RBD), depression, anxiety, and Unified Parkinson's Disease Rating Scale Part II and Par
47 nt Disorder Society-sponsored version of the Unified Parkinson's Disease Rating Scale Part III (MDS-U
48 hn and Yahr score of 2 or greater, and had a Unified Parkinson's disease rating scale part III (UPDRS
49 cale for 3 h post-dose and maximum change of Unified Parkinson's Disease Rating Scale part III for 3
52 n motor function, as blindly assessed on the Unified Parkinson's Disease Rating Scale, part III (UPDR
53 mplications (as assessed with the use of the Unified Parkinson's Disease Rating Scale, parts III, II,
54 son's disease patients, as determined by the Unified Parkinson's Disease Rating Scale (r = -0.7, P =
55 a significant overall model for total motor Unified Parkinson's Disease Rating Scale scores (F = 11.
56 r, posterior, and whole SNpc correlated with Unified Parkinson's Disease Rating Scale scores (r(2) =
57 teristic analyses, and correlations with the Unified Parkinson's Disease Rating Scale scores were tes
59 aying different activities with preoperative Unified Parkinson's Disease Rating Scale subscores (OFF
63 in the off-medication motor sub-score of the Unified Parkinson's Disease Rating Scale (UPDRS) and a 6
64 asures were the annual rate of change in the unified Parkinson's disease rating scale (UPDRS) and the
65 Clinical evaluation included the use of the Unified Parkinson's Disease Rating Scale (UPDRS) before
66 rimary outcome was a change in scores on the Unified Parkinson's Disease Rating Scale (UPDRS) between
67 th a score of 1 or greater on item 14 of the Unified Parkinson's Disease Rating Scale (UPDRS) in the
68 k activity, caudate/putamen DAT binding, and Unified Parkinson's Disease Rating Scale (UPDRS) motor r
69 inical improvement as measured by changes in Unified Parkinson's Disease Rating Scale (UPDRS) motor r
70 ntial improvements in contralateral hemibody Unified Parkinson's Disease Rating Scale (UPDRS) motor s
71 rs, were in Hoehn and Yahr stage 3-4 and had unified Parkinson's disease rating scale (UPDRS) motor s
72 on's disease and an overnight off-medication unified Parkinson's disease rating scale (UPDRS) motor s
73 t recipients, as indicated by a reduction in Unified Parkinson's Disease Rating Scale (UPDRS) motor s
74 rimary outcome measure was the contralateral Unified Parkinson's Disease Rating Scale (UPDRS) motor s
75 in the off-medication motor subscore of the Unified Parkinson's Disease Rating Scale (UPDRS) of 14 p
76 s disease patients with a median total motor Unified Parkinson's Disease Rating Scale (UPDRS) of 52.5
77 roSavin and motor responses as assessed with Unified Parkinson's Disease Rating Scale (UPDRS) part II
78 ine confounding variables with regard to the Unified Parkinson's Disease Rating Scale (UPDRS) Part II
79 ys, atypical or drug-induced parkinsonism, a Unified Parkinson's Disease Rating Scale (UPDRS) rest tr
80 ary outcome variable was the change in total Unified Parkinson's Disease Rating Scale (UPDRS) score a
82 ary outcomes included descriptive results of Unified Parkinson's Disease Rating Scale (UPDRS) scores
83 difficulty (PIGD), based on pre-DBS baseline Unified Parkinson's Disease Rating Scale (UPDRS) scores
84 logical rating scales; following UPVP, Total Unified Parkinson's Disease Rating Scale (UPDRS) scores
85 There were no significant differences in Unified Parkinson's Disease Rating Scale (UPDRS) Section
86 the Sensory Organization Test (SOT) and the Unified Parkinson's Disease Rating Scale (UPDRS) subscal
88 e was assessed with subset categories of the Unified Parkinson's Disease Rating Scale (UPDRS), timed
90 points of the primary analysis based on the Unified Parkinson's Disease Rating Scale (UPDRS, a 176-p
91 r status was evaluated using part III of the Unified Parkinson's Disease Rating Scale (UPDRS-III), in
93 yndrome only in the patient's left hemibody (Unified Parkinson's Disease Rating Scale [UPDRS] part II
94 ed with a modest clinical improvement on the Unified Parkinson's Disease Rating Scale, whereas the im
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。